Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
17 evidence topics · 12 sources
Summary: anticipated population and place in treatment
Lysergide (DT120 ODT) is investigational; the sponsor anticipates an NDA filing in the first half of 2027, states that its clinical trials are currently the appropriate way to receive the drug, and is evaluating when expanded access may be made available. The sponsor's 2026 corporate presentation counts 4.2 million U.S. adults with GAD or MDD failed by two or more prescription treatments, of 13 million treated with prescription drugs. In the Voyage trial, 78 of 214 participants (36%) had two or more past GAD medications, 65 (30%) had one, and 71 (33%) had none. The sponsor reports that payers expect to manage use with prior authorization in line with other branded psychiatric products. The NICE guideline places complex treatment-refractory GAD at step 4, managed with specialist care such as complex drug or psychological regimens and multi-agency input. One author names, as conditions for adoption, full peer-reviewed reporting of the Voyage and Panorama topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable model of monitored care.
Summary: care setting, monitoring, and scheduling
The studied paradigm is a single dosing visit with no psychotherapy, continuous monitoring by dosing session monitors, an end of session when checklist criteria are met, and follow-up visits for assessment only. The Phase 3 trials required 8 hours of monitoring; average time to checklist clearance was 5.8 to 6.4 hours across Emerge, Voyage, and Panorama (Part A), and normal activities, including driving, resume the next day. The sponsor proposes 5 to 8 hours of monitoring through the checklist, which it intends to reflect requirements under a potential REMS. It plans delivery through certified third-party treatment sites, citing ~4,000 interventional psychiatry clinics (about half of the estimated Spravato REMS sites), and is engaged with the VA. Lysergide is a Schedule I substance: after FDA approval, the DEA and states must reschedule the product before it can be marketed, state scheduling may delay sale, and the active ingredient would remain subject to manufacturing quotas.
Target population named by the company: adults failed by two or more treatments
| Population | Quoted count | Quoted description |
|---|---|---|
| U.S. adults with GAD or MDD | “50 million” | “US Adults with GAD / MDD” |
| Diagnosed | “26 million” | “Diagnosed with GAD / MDD” |
| Treated with prescription drugs | “13 million” | “Rx Treated” |
| Failed by two or more prescription treatments | “4.2 million” | “Failed by 2+ Rx” |
Guideline step for treatment-refractory GAD: NICE stepped care
Treatment paradigm: single administration without psychotherapy
Session length and real-world delivery model
Monitoring duration proposed for commercial use
Care setting: interventional psychiatry clinics
| Item | Quoted value |
|---|---|
| Slide title | “Modest Adoption Yields Significant Opportunity Given Large and Growing Delivery Ecosystem” |
| Interventional psychiatry clinics | “~4,000” |
| Basis for the clinic count | “Represents approximately half of estimated number of sites in the Spravato® REMS program.” |
| Price assumption | “Assumes midpoint of surrogate pricing range for Spravato®. The price of DT120 ODT has not been established.” |
Supervised treatment model and referral pathways: third quarter 2026 earnings call
Department of Veterans Affairs as a care setting
Monotherapy as the studied use and combination use as anticipated practice
Payer expectations reported by the company
Session monitoring expected by FDA in clinical investigations of psychedelic drugs
Supervised-administration analog: esketamine REMS
Procedure codes for monitoring during psychedelic medication therapy
Conditions for adoption named in a drug review
“The phase 2b dose-finding study provides a credible signal of rapid and durable anxiolytic activity after one 100 microgram administration without protocol-mandated psychotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adoption will depend on full peer-reviewed reporting of the positive Voyage and Panorama phase 3 topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable monitored-care model.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote